Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUOPANC II
NL-OMON59794Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sgm-101 in pancreatic adenocarcinoma (PDAC), sponsored by Leiden University Medical Center. Primary endpoint: Visualization of primary tumor and extent. Started Dec 2023; status: completed.
02
Drugs
sgm-101
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59794.